Engflag

Zedprex

Quick links to important sections

Zedprex

Zedprex_PL

Method of action: Antidepressant, Psychoanaleptics, Timoleptic

Treatment option: Bulimia, Bulimia Nervosa, Depression, Neurosis, Obsessive Compulsive Personality Disorder

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zedprex

Quick Facts: Zedprex (Fluoxetine)

Property Description
Active ingredient Fluoxetine hydrochloride
Form Capsule, Tablet, Oral Solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Typical use Mood regulation and stabilization
Origin Synthetic, Small Molecule
Differentiation Available as a highly water-soluble oral solution, useful for patients with difficulty swallowing.

What Type of Medicine is Zedprex?

Zedprex is a trade name for the active ingredient Fluoxetine hydrochloride, which is classified as a psychotropic medicine and belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class of antidepressants. This designation is clinically recognized because Fluoxetine was the first molecule of this generation of antidepressants, setting the standard for the development of subsequent SSRI therapies. The active substance is a synthetic, small molecule and is confirmed as a single-ingredient prescription agent designed for oral administration.

Composition and Available Forms of Fluoxetine

The active substance in the medicine is Fluoxetine hydrochloride. It is formulated as a single-ingredient drug for oral use, meaning it is taken by mouth, and it is available in several high-level dosage forms, including the standard capsule (and delayed-release variants), a compressed tablet, and an oral solution. The availability of the highly water-soluble oral solution distinguishes the preparation, offering an important administrative option, particularly for patients who have difficulty swallowing solid forms.

What is the General Purpose of an SSRI Antidepressant?

The general purpose of this type of SSRI antidepressant is to provide long-term pharmacological support for emotional and mood stability by helping to restore a necessary neurochemical balance in the brain. Fluoxetine achieves this by gently and selectively delaying the reabsorption, or reuptake, of the neurotransmitter serotonin. By increasing the availability of serotonin to crucial communication pathways, the drug supports the brain's ability to regulate emotion, which is the foundational therapeutic goal for addressing difficulties related to chronic mood dysregulation.

Regulatory References

  1. NIH

What side effects are possible with Zedprex?

Adverse Reaction Scope

The medicine's safety profile is officially documented by frequency and the body system affected. Adverse reactions are frequently grouped as Nervous System Disorders, Psychiatric Disorders, and Gastrointestinal Disorders.

Frequency Classification Key Adverse Reactions (Examples)
Very Common (Affects > 1 in 10) Headache, Insomnia, Nausea, Diarrhea, and Fatigue/Asthenia
Common (Affects 1 to 10 in 100) Dizziness, Somnolence (Drowsiness), Anxiety, Decreased Appetite, Dry mouth, and Sexual dysfunction

Serious adverse reactions are defined in regulatory documents. These include the rare, potentially life-threatening condition Serotonin Syndrome or Neuroleptic Malignant Syndrome-like events, and severe skin disorders such as Stevens-Johnson syndrome. The potential for Activation of Mania/Hypomania is also officially noted.

Safety-Related Constraints and Considerations

Official labeling contains specific notes related to patient populations and exposure patterns:

  • Pediatric and Young Adults (Up to age 25): The label includes a mandatory Boxed Warning regarding the increased risk of Suicidal Thoughts and Behavior observed in this age group.
  • Hepatic Impairment: Due to prolonged clearance, specific dosing considerations are required for patients with impaired liver function.
  • Exposure Patterns: Side effects such as anxiety and insomnia are often reported in the initial weeks of therapy or following dose increases. Separately, specific discontinuation symptoms are listed as potential occurrences upon cessation of treatment.
  • High-Level Constraints: Safety risks officially noted include the potential for Seizures, Hyponatremia (low sodium levels), and an increased risk of Abnormal Bleeding.

Regulatory Safety Summary

The regulatory safety structure formally defines risks by frequency and body system, providing a clear classification of common expected events and rare serious risks. The profile explicitly mandates a Boxed Warning for suicidal thinking in younger individuals and notes risks like Serotonin Syndrome and the need for caution in the presence of risk factors for QT prolongation.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Zedprex

Overdose Scope

Entity Official Regulatory Statement
Documented overdose presentations Presentation includes tremor, agitation, confusion, dizziness, somnolence, nausea, and vomiting.
Physiological systems affected The Central Nervous System (CNS) and Cardiovascular system are principally affected, with manifestations including seizures and cardiac rhythm disturbances.
Dose-related or exposure-related factors Severe outcomes are more likely when ingested in combination with other serotonergic drugs or alcohol.
Population-specific overdose notes Elderly patients and those with pre-existing cardiac conditions or hepatic impairment require heightened monitoring during management.
Emergency-response statements Symptomatic and supportive treatment is the primary recommended intervention. ECG monitoring is required. Gastric lavage or activated charcoal may be considered in specific circumstances.
When immediate medical help is required Seek immediate medical attention or call a Poison Control Center/emergency services whenever an overdose is suspected or symptoms of toxicity are present.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Potential for severe and life-threatening complications, including Serotonin Syndrome and Ventricular arrhythmia (e.g., Torsades de Pointes).
Regulatory basis Information is consistent with the overdose descriptions found in the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).
Overdose-context constraints Due to the long half-lives of fluoxetine and its active metabolite, extended observation and close clinical monitoring are necessary.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with CNS signs such as seizures, tremor, and confusion, alongside gastrointestinal disturbances.
  • Severe outcomes include Serotonin Syndrome, coma, and cardiac toxicity with QT prolongation and the risk of Ventricular arrhythmia.
  • No specific antidote is known; management requires symptomatic and supportive treatment under continuous ECG monitoring.
  • It is mandatory to seek immediate medical attention whenever an overdose is suspected.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile of Zedprex by focusing on the acute risks of central nervous system hyperexcitability and severe cardiovascular disturbances. This necessitates that emergency medical care be sought immediately, as regulators specifically mandate close observation and continuous monitoring due to the potential for life-threatening complications. Since no specific reversing agent is available, the regulatory guidance strictly emphasizes supportive clinical management in a hospital setting.

Therapeutic Uses of Zedprex

Main Therapeutic Uses

Zedprex is a medication belonging to the class of selective serotonin reuptake inhibitors (SSRIs). It is primarily used in the management of several psychological and emotional conditions by influencing the balance of serotonin in the brain.

Depressive Disorders

The primary application of Zedprex is the treatment of major depressive episodes. It is used to help alleviate persistent feelings of sadness, loss of interest in daily activities, and the physical fatigue often associated with clinical depression. The goal of treatment in this context is to improve mood and restore functional capacity.

Obsessive-Compulsive Disorder (OCD)

Zedprex is used to manage the symptoms of obsessive-compulsive disorder. This includes reducing the frequency and intensity of persistent, unwanted thoughts (obsessions) and the repetitive behaviors (compulsions) that individuals feel driven to perform. Treatment aims to reduce the interference these symptoms have on daily life.

Bulimia Nervosa

This medication is indicated as a complement to psychotherapy for the treatment of bulimia nervosa. It is specifically used to help reduce binge-eating episodes and purging activities (self-induced vomiting or the use of laxatives).

Panic Disorder

Zedprex may be used in the treatment of panic disorder, with or without agoraphobia. It helps in reducing the frequency of sudden panic attacks and the anticipatory anxiety regarding future episodes.

Anticipated Benefits and Therapeutic Goals

  • Mood Stabilization: By increasing the availability of serotonin, the medication helps stabilize emotional responses and improve overall outlook.
  • Symptom Reduction: The therapy focuses on decreasing the severity of specific psychological symptoms, such as intrusive thoughts or compulsive rituals.
  • Support for Daily Functioning: Successful treatment is intended to help individuals resume social, professional, and personal activities that may have been disrupted by their condition.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zedprex?

The official eligibility for Zedprex (Fluoxetine) is strictly defined by regulatory documents, outlining populations for whom use is permitted, restricted, or absolutely prohibited.

Contraindicated Populations Restricted Use Populations (Conditional Eligibility)
Patients currently taking a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue. Patients with Hepatic Impairment (e.g., cirrhosis), requiring a lower or less frequent dosage.
Patients currently taking Pimozide or Thioridazine. The Elderly (geriatric patients), who may require lower or less frequent dosing.
Patients with a known hypersensitivity to Fluoxetine or its excipients. Patients with a history of seizures or those with cardiac risk factors (e.g., congenital long QT syndrome), requiring cautious use.

Eligibility for use in children and adolescents is defined by age thresholds: it is approved for Major Depressive Disorder (MDD) in patients aged 8 to 18 years and for Obsessive-Compulsive Disorder (OCD) in patients aged 7 to 17 years. Safety and effectiveness are not established below these age cut-offs.

For Pregnancy, use is conditional and allowed only if the potential benefit justifies the potential risks to the fetus. Breastfeeding is not recommended while using the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zedprex (Fluoxetine) has officially documented interactions with several classes of medicinal products, necessitating specific restrictions and monitoring requirements.

Interaction Mechanism/Category Representative Interacting Agents Regulatory Requirement/Constraint
Serotonergic Effects Monoamine Oxidase Inhibitors (MAOIs), Triptans, Tramadol, Linezolid, Intravenous Methylene Blue, Tryptophan, St. John's Wort Co-use with MAOIs (including isocarboxazid, phenelzine, tranylcypromine, linezolid, and intravenous methylene blue) is Contraindicated due to the risk of Serotonin Syndrome. Mandatory washout periods must be observed: 14 days after discontinuing an MAOI before starting Fluoxetine, and at least 5 weeks after discontinuing Fluoxetine before starting an MAOI. Caution is advised with other serotonergic agents.
CYP2D6 Inhibition Pimozide, Thioridazine, Tricyclic Antidepressants (TCAs), Flecainide, Propafenone, Haloperidol, Clozapine Fluoxetine is a potent inhibitor of the CYP2D6 enzyme pathway, leading to elevated plasma concentrations of co-administered drugs primarily metabolized by CYP2D6. Use with Pimozide and Thioridazine is Contraindicated due to the risk of QTc prolongation; Thioridazine should not be used within 5 weeks of stopping Fluoxetine. Monitoring of TCA plasma levels is required during co-administration and after Fluoxetine discontinuation.
Bleeding Risk Warfarin, Aspirin, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Co-administration with drugs that interfere with hemostasis, such as warfarin, aspirin, and NSAIDs, may potentiate the risk of bleeding.

These restrictions establish that the drug's official interaction profile is defined by two major concerns: the serotonergic consequences of co-administration and the pharmacokinetic effects resulting from its potent inhibition of CYP2D6. Regulatory documents strictly mandate long washout periods for MAOIs and list specific agents, such as Pimozide and Thioridazine, as absolute contraindications due to increased systemic exposure and cardiac risk. These required constraints structure the safe use of the product when combined with other active medicines.

Mechanism of Action

The action of Zedprex (Fluoxetine) is based on a structured, time-dependent process that modulates central nervous system signaling and neuroadaptation. The drug's mechanism is defined by three interconnected physiological domains. The immediate molecular action is the highly selective blockade of the Serotonin Transporter ( SERT) protein, which prevents the rapid reuptake of Serotonin ( 5-HT). This inhibition instantly increases 5-HT concentration in the synaptic cleft, initiating the mechanistic cascade. The sustained elevation of synaptic 5-HT triggers a delayed adaptive response through the desensitization and reduction of 5-HT1A autoreceptors. This long-term functional change removes the inhibitory feedback on 5-HT release, allowing the system to achieve a more robust and sustained level of serotonergic signaling. Beyond these signaling changes, the persistent stabilization promotes an integrative mechanistic cascade that enhances neuronal plasticity. This involves upregulating factors like BDNF, which is associated with the structural remodeling and stabilization of CNS circuits associated with emotional and behavioral regulation. The mechanism facilitates the long-term neuroadaptive restructuring of these systems.

Dosage and Administration Information

Zedprex (Fluoxetine) is administered exclusively by the oral route, available as an immediate-release capsule, compressed tablet, or liquid oral solution. The medicine is intended to be taken with or without food, allowing flexibility in its daily timing.

The treatment follows standardized, indication-specific dosing regimens. For Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD), the initial dose is typically 20 mg once daily. The standard maintenance dose ranges from 20 mg to 60 mg per day, with the official maximum dose set at 80 mg daily. The regimen for Bulimia Nervosa is a fixed 60 mg once daily dose, usually taken in the morning.

The frequency pattern is predominantly once daily. However, a 90 mg delayed-release capsule is approved for once-weekly administration for certain uses, requiring a distinct schedule. If discontinuation of long-term therapy is necessary, a gradual dose reduction process (tapering) must be employed, as outlined in official documentation, to ease the transition.

Dose adjustments are officially mandated for specific populations. Patients with hepatic impairment may require a lower dose or less frequent dosing (e.g., every other day) due to reduced drug clearance. Furthermore, specific initial doses (e.g., 10 mg) and maintenance ranges are established for approved pediatric indications in older children and adolescents.

Recent Clinical Evidence

Research evidence / Overview of studies for Zedprex (Fluoxetine)

The clinical research for Zedprex (Fluoxetine) is primarily built on formal clinical evaluation studies, including randomized controlled trials (RCTs), which are used for the clinical evaluation of how symptom patterns are measured in specific populations. The evidence is reviewed by government regulatory bodies to understand the drug's research profile and the context in which indications were approved.

Research Studies for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

For Major Depressive Disorder (MDD), research examined changes in symptoms during periods of increased symptom activity. Studies included short-term RCTs and longer continuation trials. In adult populations, studies reported patterns of measurements on depression scales that were statistically differentiated from the outcomes seen in the placebo group. The research for acute treatment is often limited to short-term data (12 weeks or less), meaning long-term outcomes are not fully established.

For Obsessive-Compulsive Disorder (OCD), studies explored how Fluoxetine was evaluated in conditions characterized by heightened symptoms. The research monitored the severity and frequency of obsessive thoughts and compulsive behaviors in adults and pediatric populations (aged 7 years and older). Findings were generally consistent across these trials, but there is limited information for long-term outcomes.

Research Studies for Panic Disorder and Bulimia Nervosa

For Panic Disorder, research was conducted using acute, placebo-controlled trials. Outcomes monitored included the frequency of full-symptom panic attacks. Trials reported that a numerically higher percentage of patients receiving Fluoxetine met the study's definition of "panic-free status" at the study endpoint compared to the placebo group. Follow-up durations were limited.

For Bulimia Nervosa, studies explored the effect on weekly frequency of binge eating and purging episodes in adult study populations. Research highlights changes measured during the study period compared to the placebo group. However, the existing studies provide limited insight into long-term maintenance of the behavioral outcomes.

What is Still Uncertain in the Research Landscape

The body of research contains gaps where further data would provide greater context. Long-term effects are not fully established across all studied populations and indications. For several conditions, the sample sizes were modest in the key studies, and comparative evidence is lacking for certain subgroups. The research provides context but not individual predictions, as findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Zedprex (FAQ)

Q: What is the primary substance in Zedprex?

Zedprex contains the active substance fluoxetine. Fluoxetine is a type of medicine known as a selective serotonin reuptake inhibitor (SSRI). According to the official product information, it works by helping to increase the level of a natural substance called serotonin in the brain.

Q: Does Zedprex treat depression?

Regulatory documents state that Zedprex is approved for the treatment of major depressive episodes in adults. It is also sometimes indicated for depression in children and adolescents, but this is always subject to specific guidelines outlined in the official documentation.

Q: Is Zedprex used for obsessive-compulsive disorder (OCD)?

Yes, official product information confirms that Zedprex is indicated for the treatment of obsessive-compulsive disorder (OCD) in adults. Studies indicate it can be used to help manage the intrusive thoughts and repetitive behaviors associated with this condition.

Q: Can Zedprex be used for the eating disorder bulimia nervosa?

According to the regulatory sources, Zedprex is approved specifically for the treatment of bulimia nervosa in adults. The official information states it is used as a complement to psychotherapy, and it may be used to complement treatment for related behaviors.

Q: Is there a maximum time someone can take Zedprex?

Official information indicates that the duration of treatment with Zedprex is determined individually by a healthcare professional. Official information indicates that continued treatment after improvement is often recommended to help prevent relapse. There are no fixed maximum limits described in the general regulatory documents.

Q: If I miss a dose of Zedprex, what should I do?

Official product information generally suggests taking a missed dose when it is remembered. However, if it is almost time for the next scheduled dose, official information advises skipping the forgotten one. Taking a double dose is generally advised against in the product documentation.

Q: How should I stop taking Zedprex?

Official product information states that sudden discontinuation of Zedprex is generally not recommended. Official documents indicate that stopping treatment typically involves gradually reducing the dose over a period of time. This method is used to help minimize potential withdrawal reactions.

How should Zedprex be stored and disposed of?

Storage and Protection Requirements

Zedprex (Fluoxetine) must be stored at controlled room temperature, generally maintained between 20 C and 25 C (68 F and 77 F). The official label permits temporary temperature excursions between 15 C and 30 C (59 F and 86 F). The product must be stored in its original, tightly closed container and explicitly protected from light and moisture. The oral solution form has the specific mandatory handling instruction Do not freeze.

Stability and Child Safety

All forms must be kept out of the sight and reach of children. For the oral solution, some regulatory documents specify that the unused portion must be discarded 60 days after first opening to maintain product stability. Do not use the medicine beyond the expiry date printed on the packaging.

Official Disposal Rules

The FDA and other authorities recommend disposing of unused or expired medicine through a designated drug take-back program. If this option is not available, the product may be mixed with an undesirable substance (e.g., used coffee grounds or dirt), placed in a sealed container, and thrown into the household trash. Do not flush the medicine unless specifically instructed, and remove or scratch out all personal information from the container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTurkey

Equivalent of Zedprex found in:

A-Z Index: